Mario-3 Phase Ii Study Safety Run-In Evaluating A Novel Triplet Combination Of Eganelisib (Formerly Ipi-549), Atezolizumab (Atezo), And Nab-Paclitaxel (Nab-Pac) As First-Line (1l) Therapy For Locally Advanced Or Metastatic Triple-Negative Breast Cancer (Tnbc)